Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA CHOICE FOR GENERICS OFFICE DIRECTOR IS GENELABS' ROGER

Executive Summary

FDA CHOICE FOR GENERICS OFFICE DIRECTOR IS GENELABS' ROGER WILLIAMS; the agency is in the process of sending the recommendation to HHS Secretary Sullivan. CDER Deputy Director Gerald Meyer announced the agency's decision at a March 15 Food and Drug Law Institute meeting on advisory committees and FDA. In his new position at FDA, Williams will replace Bruce Burlington, who has been serving as acting director since the office was created. A physician, Williams joined Genelabs in September as the company's medical director and has been overseeing the progress of clinical trials of Genelabs' GLQ223 antiviral compound for AIDS. Prior to that, Williams was director of the University of California-San Francisco School of Pharmacy Drug Studies Unit. In that position, he had been working on Bolar's new bioequivalence studies for its generic version of Dyazide (triamterene/hydrochlorothiazide). Williams also performed the original biostudies for Mylan's Maxzide. Reportedly, when Williams was interviewed in November for the position, CDER Director Peck, MD, favored him as the top candidate ("The Pink Sheet" Nov. 27, "In Brief"). However, his prior involvement in biostudies for generic firms was an apparent hurdle to his nomination. Noting that "the person that we are in the process of appointing for the office of generic drugs is someone who is currently working for a firm and has in the past been heavily involved in the testing of products for a variety of firms," Meyer indicated that some FDA topsiders may have had reservations about Williams' nomination because "we sort of have a view that people from industry will be totally inappropriate."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS017114

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel